Prevention of EAE by tolerogenic vaccination with PEGylated antigenic peptides.
Jennifer PfeilMario SimonettiUta LauerBianca von ThülenPawel DurekChristina PoulsenJustyna PawlowskaMatthias KrögerRalf KrähmerFrank LeendersUte HoffmannAlf HamannPublished in: Therapeutic advances in chronic disease (2021)
PEGylation of antigenic peptides is an effective and feasible strategy to improve tolerogenic (Treg-inducing) peptide-based vaccines, but application for immunotherapy of overt disease might require modifications or combination therapies that simultaneously suppress effector mechanisms.